Late-stage opportunity EyePoint is in Phase 3 global pivotal trials for wet AMD with topline data anticipated in 2026, presenting a near-term opportunity for strategic partnerships, co-development, or advisory collaborations to accelerate commercialization and leverage their sustained delivery platform.

DME momentum A positive Phase 2 in diabetic macular edema with Phase 3 pivotal planning underway indicates potential expansion opportunities to secure licensing, distribution, or co-promotion deals for a broader retina portfolio targeting patients with diabetic eye diseases.

Strategic leadership Recent executive additions including a Senior Vice President and Chief Strategic Science Officer and a Chief Commercial Officer signal a readiness to scale commercial operations, creating openings for strategic alliances, market access discussions, and targeted sales partnerships.

Financial runway With substantial funding and a recent public offering reinforcing liquidity, EyePoint is positioned to pursue collaborations and in-licensing opportunities for its sustained-delivery VEGF inhibitor platform, potentially attracting joint development or grant-funded initiatives.

Competitive positioning Four approved drugs across three decades and tens of thousands of treated eyes establish EyePoint as an experienced retina-focused player in a competitive landscape, making it a strong candidate for OEM collaborations, contract manufacturing, and distribution partnerships to broaden reach.